author-photo

Andre C. Schuh

University Health Network
University of Toronto

135

Papers

7069

Citations

Citation Trend

Filter By

Papers (100) Sort By

Journal Conference Others

Maintenance Chemotherapy in Acute Promyelocytic Leukemia: The Thin Line Between Survival and Immunosuppression

2020
Show All
- Source
- Cite
- Save
Citations (0)
Anticoagulation prophylaxis reduces venous thromboembolism rate in adult acute lymphoblastic leukaemia treated with asparaginase-based therapy.

2020 British Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (8)
Geographical Distance from Quaternary Treatment Center Does Not Impact Choice of Upfront Therapy, Clinical Trial Participation and Outcomes in Patients with Newly Diagnosed AML

2020 Blood
Show All
- Source
- Cite
- Save
Citations (0)
CLONAL HEMATOPOIESIS ASSOCIATED MUTATIONS, CARDIOVASCULAR EVENTS, AND ALL-CAUSE DEATH AMONG PATIENTS WITH ACUTE MYELOID LEUKEMIA

2020 Journal of the American College of Cardiology
Show All
- Source
- Cite
- Save
Citations (0)
Risk of Thrombosis in Adult Philadelphia-Positive ALL Treated with an Asparaginase-Free ALL Regimen

2020 Current Oncology
Show All
- Source
- Cite
- Save
Citations (0)
AML-063: A Randomized, Double-Blind, Placebo-Controlled Study of Venetoclax with Azacitidine Versus Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia Ineligible for Intensive Therapy-Viale-A

2020 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (4)
CC-486 Improves Overall Survival (OS) and Relapse-Free Survival (RFS) for Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC), Regardless of Amount of Consolidation Received: Results from the Phase III QUAZAR AML-001 Maintenance Trial

2020 Blood
Show All
- Source
- Cite
- Save
Citations (5)
PATIENTS WITH RELAPSED MIXED PHENOTYPE ACUTE LEUKEMIA HAVE SHORT REMISSION DURATION WITH RE-INDUCTION: A SINGLE CENTER EXPERIENCE: PS961

2019
Show All
- Source
- Cite
- Save
Citations (1)
ASSESSMENT OF MOLECULAR MRD KINETICS BY ERROR-CORRECTED NEXT-GENERATION SEQUENCING PROVIDES INDEPENDENT PROGNOSTIC INFORMATION IN ADULT AML PATIENTS: PS1027

2019
Show All
- Source
- Cite
- Save
Citations (1)
Safety and Clinical Activity of Mutant IDH1 Inhibitor IVOSIDENIB (IVO; AG-120) In Combination with AZACITIDINE (AZA) for Newly Diagnosed Acute Myeloid Leukemia (ND AML)

2019 Annals of Hematology
Show All
- Source
- Cite
- Save
Citations (1)